- Previous Close
10.79 - Open
10.64 - Bid 7.49 x 200
- Ask 13.18 x 200
- Day's Range
10.20 - 10.70 - 52 Week Range
8.67 - 17.82 - Volume
210,908 - Avg. Volume
860,618 - Market Cap (intraday)
653.036M - Beta (5Y Monthly) 0.97
- PE Ratio (TTM)
-- - EPS (TTM)
-0.81 - Earnings Date May 5, 2025 - May 9, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
23.57
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
www.evolus.com332
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: EOLS
View MorePerformance Overview: EOLS
Trailing total returns as of 4/21/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: EOLS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: EOLS
View MoreValuation Measures
Market Cap
686.10M
Enterprise Value
729.13M
Trailing P/E
--
Forward P/E
107.53
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.51
Price/Book (mrq)
124.25
Enterprise Value/Revenue
2.74
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-18.93%
Return on Assets (ttm)
-8.08%
Return on Equity (ttm)
--
Revenue (ttm)
266.27M
Net Income Avi to Common (ttm)
-50.42M
Diluted EPS (ttm)
-0.81
Balance Sheet and Cash Flow
Total Cash (mrq)
86.95M
Total Debt/Equity (mrq)
2,353.84%
Levered Free Cash Flow (ttm)
-4.68M